Azithromycin Protects Against SO2 Induced Lung Injury

REYKJAVIK, ICELAND – 21 September 2020 – EpiEndo Pharmaceuticals (www.epiendo.com) is pleased to share important findings in a poster at the ERS (European Respiratory Society) International Congress this year. To find out more please see our publication:

Azithromycin ameliorates sulfur dioxide-induced airway epithelial damage and inflammatory responses

Joelsson, J.P., Kricker, J.A., Arason, A.J. et al. Azithromycin ameliorates sulfur dioxide-induced airway epithelial damage and inflammatory responses. Respir Res 21, 233 (2020). https://doi.org/10.1186/s12931-020-01489-8

The airway epithelium (AE) forms the first line of defence against harmful particles and pathogens. Barrier failure of the airway epithelium contributes to exacerbations of a range of lung diseases that are commonly treated with Azithromycin (AZM). In addition to its anti-bacterial function, AZM has immunomodulatory effects which are proposed to contribute to its clinical effectiveness. In vitro studies have shown the AE barrier-enhancing effects of AZM. The aim of this study was to analyze whether AE damage caused by inhalation of sulfur dioxide (SO2) in a murine model could be reduced by pre-treatment with AZM. https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-01489-8

#EpiEndo #COPD #Barrierprotection

Azithromycin protects against SO2 induced lung injury